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The RET proto-oncogene encodes a functional receptor
tyrosine kinase (Ret) for the Glial cell line Derived
Neurotrophic Factor (GDNF). RET is involved in several
neoplastic and non-neoplastic human diseases. Oncogenic
activation of RET is detected in human papillary thyroid
tumours and in multiple endocrine neoplasia type 2
syndromes. Inactivating mutations of RET have been
associated to the congenital megacolon, i.e. Hirsch-
prung’s disease. In order to identify pathways that are
relevant for Ret signalling to the nucleus, we have
investigated its ability to induce the c-Jun NH2-terminal
protein kinases (JNK). Here we show that triggering the
endogenous Ret, expressed in PC12 cells, induces JNK
activity; moreover, Ret is able to activate JNK either
when transiently transfected in COS-1 cells or when
stably expressed in NIH3T3 fibroblasts or in PC Cl 3
epithelial thyroid cells. JNK activation is dependent on
the Ret kinase function, as a kinase-deficient RET
mutant, associated with Hirschsprung’s disease, fails to
activate JNK. The pathway leading to the activation of
JNK by RET is clearly divergent from that leading to
the activation of ERK: substitution of the tyrosine 1062
of Ret, the Shc binding site, for phenylalanine abrogates
ERK but not JNK activation. Experiments conducted
with dominant negative mutants or with negative
regulators demonstrate that JNK activation by Ret is
mediated by Rho/Rac related small GTPases and,
particularly, by Cdc42.
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Introduction
RET encodes a tyrosine kinase receptor (Ret)
(Takahashi et al., 1988), which is expressed, during
embryogenesis, in kidney and nervous system, includ-
ing neurons of the enteric tract. Consistently, RET-
deficient mice show lack of enteric neurons and renal
dysgenesis (Schuchardt et al., 1994), and ‘loss of
function’ RET mutations are associated with Hirsch-
sprung’s disease (Romeo et al., 1994; Edery et al.,
1994; Pasini et al., 1995; Carlomagno et al., 1996),
which is characterized by the congenital defect of
intestinal innervation. Recently, GDNF (glial cell line
derived neurotrophic factor) has been identified as one
functional ligand for Ret. GDNF binds to GDNFR-a,
a glycosyl phosphatidylinositol-linked cell surface
receptor, which, in turn, mediates Ret activation (Jing
et al., 1996; Treanor et al., 1996). Consistent with that,
mice with targeted disruption of the GDNF gene show
a phenotype similar to that of RET knock-out mice
(Sanchez et al., 1996).
Deregulation of the RET function has been
demonstrated to be oncogenic. RET activation by
gene rearrangement is found in nearly 40% of sporadic
thyroid papillary carcinomas. These rearrangements
lead to the fusion of its tyrosine kinase encoding
domain to heterologous genes, generating the chimeric
RET/PTC oncogenes (Grieco et al., 1990). RET/PTC1,
the one more frequently isolated, is generated by the
fusion of RET to the 5'-terminal region of a gene
designated H4 (Grieco et al., 1990). In addition,
germline RET point mutations, responsible for the
inheritance of the MEN2A (multiple endocrine
neoplasia type 2A), MEN2B, and FTMC (familial
medullary thyroid carcinoma) syndromes (Donis-Keller
et al., 1993; Mulligan et al., 1993; Carlson et al., 1994;
Hofstra et al., 1994), also lead to an activation of the
transforming potential of RET (Santoro et al., 1995;
Asai et al., 1995). In most of MEN2A and FMTC
cases substitution of extracellular cysteines leads to a
constitutive dimerization of the receptor (Santoro et
al., 1995; Asai et al., 1995); in contrast, in the majority
of MEN2B cases, a M918T mutation causes a change
of Ret substrate specificity (Santoro et al., 1995;
Songyang et al., 1995).
Receptor tyrosine kinases’ signals are, at least in
part, transduced by intracellular serine/threonine
kinases designated MAPK (mitogen activated protein
kinases) (reviewed by Marshall, 1995). MAPK include
extracellular signal-regulated protein kinase (p44 and
p42 ERK1 and ERK2, respectively), c-Jun amino-
terminal kinases (JNKs), also designated stress-
activated protein kinase (SAPKs), and p38 kinase.
MAPK are activated by upstream dual-specific kinases.
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MEK1 and MEK2 are responsible for the activation of
the ERKs, MKK3 and MKK6 for p38, and MKK4
(also referred to as SEK or JNKK1) for JNKs
(Minden et al., 1994; Sanchez et al., 1994; reviewed
by Karin, 1995). ERKs, in turn, are able to regulate
the activity of enzymes and of nuclear proteins such as
the ternary complex factor Elk-1, involved in cell
proliferation control (reviewed by Hill and Treisman,
1995). On the other side, the two principal isoforms of
JNKs, JNK1 and JNK2, were identified by their ability
to bind and phosphorylate the amino-terminal (serines
63 and 73) domain of c-Jun (Hibi et al., 1993; Minden
et al., 1994; Kyriakis et al., 1994; Derijard et al., 1994).
Moreover, activated JNKs are able to phosphorylate at
least two other transcription factors, such as ATF-2
(Gupta et al., 1995) and Elk-1 (Whitmarsh et al., 1995).
S63/73-phosphorylated c-Jun has potent AP-1 activity
and can control the expression of a number of genes,
including c-jun itself. Several evidences demonstrate the
relevance of the JNK pathway for the establishment of
the neoplastic phenotype. The use of dominant-
negative Jun proteins (Lloyd et al., 1991) and of jun-
null fibroblasts (Johnson et al., 1996) demonstrated
that functional c-Jun is essential for Ha-ras transfor-
mation; moreover, the enhanced phosphorylation of c-
Jun is required for its cooperation with Ha-ras (Smeal
et al., 1991). Trivalent arsenic (As3+) was demonstrated
to exert its tumor promoting activity by activating
JNK1 (Cavigelli et al., 1996).
The signalling cascade leading to ERK activation
is relatively well understood. Ligand-stimulation of
receptor tyrosine kinases leads to the binding of
adaptor proteins, such as Grb2 and Shc (Pelicci et
al., 1992), containing Src homology 2 (SH2) or
phosphotyrosine-binding (PTB) domains (reviewed in
Schlessinger and Ullrich, 1992; Pawson, 1995; Hill
and Treisman, 1995). Such adapters, when bound to
the phosphorylated receptor, recruit Sos to the
plasma membrane, where it activates Ras and, thus,
the Raf-MEK1/MEK2-ERKs cascade (reviewed by
Marshall, 1995). Several evidences indicate that JNKs
are activated by a signalling cascade dierent from
that activating ERKs. Stimuli that activates JNKs are
distinct from those that enhance ERKs activity and
include ultraviolet irradiation, heat shock, changes in
osmolarity, protein synthesis inhibitors, such as
cycloheximide and anisomycin, and cytokines such
as tumour necrosis factor-a (TNF-a), and interleukin-
1. TPA (12-O-tetradecanoyl phorbol-13-acetate),
which is a potent ERK activator, has little eect
on JNK activity (Derijard et al., 1994; Kyriakis et
al., 1994). Ras, which is a potent ERK activator,
raises JNK activity only to a limited extent, and, on
the other side, Rac1 and Cdc42 small GTPases
eciently stimulate the JNK pathway without
aecting ERK activity (Coso et al., 1995a; Minden
et al., 1994, 1995). Accordingly, exchange factors
(GEF) for Rac1 and Cdc42 potently induce JNK
activity and negative modulators (RhoGAPp190 and
RhoGDI) or dominant negative mutants for Rac1
and Cdc42 (N17Rac1 and N17Cdc42) eectively
reduce JNK stimulation by EGF (Coso et al.,
1995a; Minden et al., 1995). Activated Rac1 and
Cdc42 can initiate, similarly to the Ras/Raf/MEK/
ERK pathway, a kinase cascade which stimulates
MEKK1 which, in turn, activates MKK4 (also
referred to as SEK or JNKK1), the JNK activator
(Manser et al., 1994).
Activated RET isoforms are highly transforming for
NIH3T3 cells (Grieco et al., 1990; Santoro et al., 1994;
1995; Asai et al., 1995) and are able to induce the
expression of dierentiation markers in PC12 pheo-
chromocytoma cells (Califano et al., 1995, 1996; Pasini
et al., 1995). Moreover, the RET/PTC1 oncogene is
able to transform rat thyroid epithelial PC Cl 3 cells,
causing thyrotropin-independent growth and a loss of
the dierentiated phenotype (Santoro et al., 1993), and
is able to induce thyroid carcinomas in transgenic mice
(Jhiang et al., 1996; Santoro et al., 1996). Events
following Ret activation and leading to these
transforming and dierentiating cell responses are
only partially known. Ret has been found to activate
the g isoenzyme of phospholypase C (Santoro et al.,
1994; Borrello et al., 1996), Ras (Santoro et al., 1994),
and ERKs (van Weering et al., 1995). Borrello and co-
workers have reported that Ret protein binds to and
phosphorylates Shc (Borrello et al., 1994; Asai et al.,
1996) and other groups (Lorenzo et al., 1997; Arighi et
al., 1997) have demonstrated that tyrosine residue 1062
of Ret is a binding site for the Shc-PTB domain and
that its mutation abrogates Shc binding and reduces
Ret transforming ability.
To further address the question of how Ret signals
are delivered to the nucleus, we have investigated the
ability of wild type and oncogenic Ret variants to
induce JNK activity in dierent cell types. Here we
show that Ret is able to activate JNKs through a
pathway requiring Rho/Rac-like small GTPases and
that this pathway is distinct from that leading to ERK
activation.
Results
Ret activation induces an increase of JNK activity in
NIH3T3 fibroblasts, in epithelial PC Cl 3 thyroid cells,
and in neuroepithelial PC12 cells
We have evaluated the ability of dierent RET
constructs to induce JNK activity. Figure 1 shows a
schematic representation of the Ret structure and of
the constructs used in this study. Firstly, we analysed
the phosphorylation capability of endogenus JNKs on
the glutathione S-transferase (GST)-c-Jun(79) specific
Figure 1 Schematic representation of RET structure. A scheme
of Ret1072 and Ret1114 (‘short’ and ‘long’ isoforms); the mutations
associated with HSCR (R972G), MEN2A (C634Y) and MEN2B
(M918T), analysed in this study, and the position of the
breakpoint originating RET/PTC oncogenes are shown. Tyrosine
residue 1062, which is part of a Shc PTB binding site, and which
was substituted with a phenylalanine in some experiments
(Y1062F), is also shown. SP, signal peptide; CAD, cadherin
homologous domain; CYS, cysteine-rich region; TM, transmem-
brane region; TK, tyrosine-kinase domain
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substrate by a solid-phase kinse assay (Coso et al.,
1995b). Since NIH3T3 cells do not express endogenous
Ret, we analysed JNK activity in cells stably
transfected with active RET/MEN2A and RET/
MEN2B alleles (Santoro et al., 1995). A representative
example of the assay and bar-graphs representing the
average results from three independent experiments are
reported in Figure 2a. Both activated forms of RET
were able to stimulate JNK activity at levels (*20-
fold) even higher than that caused by heat shock
treatment (*tenfold) (lane +), used as positive control
(Kyriakis et al., 1994). Also another activated form of
RET, RET/PTC1 oncogene, was able to stimulate
(*15-fold) JNK activity in NIH3T3 cells (data not
shown).
Then, we evaluated whether wild type Ret was able
to induce JNK activity when triggered by GDNF.
Since it has been demonstrated that GDNF does not
bind Ret directly but through the interaction with
GDNFR-a, we stably transfected NIH3T3-RET cells
(Santoro et al., 1995) with an expression vector for
GDNFR-a (Jing et al., 1996). A marker selected mass
population, expressing GDNFR-a, was obtained and
GDNF-induced Ret phosphorylation was demon-
strated (not shown). Untriggered NIH3T3-RET-
GDNFR-a cells showed barely detectable JNK
activity (Figure 2b). GDNF stimulation caused a
rapid (after 10 min) JNK activation in NIH3T3-RET-
GDNFR-a (Figure 2b) but not in untransfected
NIH3T3 cells (data not shown).
In order to investigate Ret signalling to JNK in cells
which are specific target for its oncogenic activation,
we analysed Ret-dependent JNK activation in a
thyroid epithelial cell line, the PC Cl 3 cell line. As
shown in Figure 3a, untrasfected PC Cl 3 cells showed
very low levels of JNK activity; this activity was
promptly induced by heat shock treatment (lane +).
PC Cl 3 cells expressing the RET/PTC1 oncogene
(Santoro et al., 1993) showed a markedly enhanced
(*tenfold) JNK activation when compared to
untransfected PC Cl 3. Accordingly, the human TPC-
1 cell line, a thyroid papillary carcinoma cell line
spontaneously harbouring a RET/PTC1 oncogene, also
showed a greatly enhanced JNK activity with respect
to a normal human thyroid cell line (data not shown).
To evaluate Ret signalling to JNK in a cell system
normally expressing Ret we selected PC12 cells, which
derive from a rat pheochromocytoma (Greene and
Tishler, 1976) and express endogenous Ret. We
transfected PC12 with GDNFR-a and obtained a
marker-selected mass population showing a readily
detectable response (Ret phosphorylation and neurite
outgrowth) to GDNF triggering (data not shown).
Then, we evaluated JNK activation upon stimulation
with GDNF, NGF (nerve growth factor), or EGF
(epidermal growth factor). PC12 cells showed signifi-
cant basal levels of JNK activity; GDNF triggering
induced JNK activation at a similar extent as NGF
and EGF, which are well-known JNK inducers (Coso
et al., 1995a) (Figure 3b). Similar levels of JNK
activation were induced in PC12 cells by heat shock
treatment (not shown).
To confirm these data with an independent assay
and to determine if the GST-c-Jun(79) phosphoryla-
tion, detected by the solid-phase kinase assay, was due
to JNK kinases including JNK1, we measured JNK1
activity by an immunocomplex kinase assay in
NIH3T3 and PC Cl 3 cells (Coso et al., 1995a).
JNK1 was immunoprecipitated with anti-JNK1 anti-
bodies and GST-c-Jun(79) was used as a substrate in
an in vitro kinase assay. NIH3T3-RET/MEN2A
showed a remarkable activation of JNK1 with respect
to untransfected cells (*sevenfold) (Figure 4). Also,
PC Cl 3-RET/PTC1 cells showed increased JNK1
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Figure 2 Ret activation of JNK in NIH3T3 cells. Solid phase kinase assay on GST-c-Jun(79) protein substrate. (a) five hundred mg
of protein lysate from control NIH3T3 (7), NIH3T3 subjected to heat shock (428C, 30 min) (+), NIH3T3 transfected with RET/
MEN2A or RET/MEN2B, were precipitated with 1 mg of GST-c-Jun(79) and incubated with radiolabelled ATP. An example of one
representative assay is reported on the left and the average results of three independent experiments, measured by phosphorimaging,
are reported on the right. Error bars are reported. (b) NIH3T3-RET-GDNFR-a were serum-starved for 12 h and stimulated with
GDNF for the indicated times. After harvesting, the GST-c-Jun(79) solid phase kinase assay was performed. The results were
typical and representative of at least three independent experiments
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activity (*eightfold). Whereas in the case of NIH3T3-
RET/MEN2A the extent of JNK activation, detected
by the immunocomplex assay, was lower than that
detected by the solid phase kinase assay (seven vs 20-
fold), in the case of PC Cl 3 cells the extent of
activation by the two methods was comparable,
suggesting that, although in NIH3T3 cells Ret is able
to activate multiple JNK isoforms, in thyroid cells one
of the major targets of Ret signalling to JNKs is the
JNK1 isoform. This can be explained by the
observation that, at a variance from NIH3T3 cells
transformed by activated RET alleles, PC Cl 3-RET/
PTC1 cells showed increased levels of JNK1 protein
(*threefold) (data not shown); thus, overexpression of
JNK1 could be part of its activation mechanism by
RET/PTC1 in thyroid cells.
Oncogenic forms of RET activate epitope-tagged JNK1
in COS-1 cells
Having ascertained that Ret is able to activate the
JNK1 isoform, to study molecules involved in this
process, we used a transient co-transfection assay in
COS-1 cells. COS-1 lack Ret receptor (Carlomagno et
al., 1996); thus, we co-transfected COS-1 with activated
forms of RET (RET/MEN2A and RET/MEN2B)
together with an HA epitope-tagged JNK1. After
transfection, the transiently expressed HA-JNK1 was
recovered by immunoprecipitation and its activity was
determined by an immunocomplex kinase assay (Coso
et al., 1995b). HA-JNK1 and RET constructs were
eciently expressed in COS-1 cells (data not shown,
and see Figure 6). Figure 5 shows that both RET/
MEN2A and RET/MEN2B induced an increase of
JNK1 activity. JNK1 stimulation by RET was as
ecient as that obtained by heat shock (lane +) or by
cycloheximide (not shown), which are known inducers
of JNK1 (Kyriakis et al., 1994; Coso et al., 1995a).
Mutations associated with Hirschsprung’s disease
(HSCR) exert a ‘loss of function’ eect on Ret;
specifically, a HSCR R972G substitution, in the TK
domain of Ret, greatly impairs both RET/MEN2A
kinase and transforming activities (Pasini et al., 1995;
Carlomagno et al., 1996). As shown in Figure 5, JNK1
stimulation in COS-1 cells was significantly impaired
when the HSCR R972G mutation was introduced in
the RET/MEN2A construct. This result indicates that
the kinase activity of Ret is required to activate JNK1
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Figure 3 (a) Activation of JNK by RET/PTC1 oncogene in thyroid cells. Five hundred mg of protein lysate from control PC Cl 3
(7), PC Cl 3 subjected to heat shock (428C, 30 min) (+), or PC Cl 3-RET/PTC1 were precipitated with 1 mg of GST-c-Jun(79) and
incubated with radiolabelled ATP. An example of one representative assay is reported on the left and the average results of three
independent experiments are reported on the right. Error bars are shown. (b) Activation of JNK by GDNF in PC12 cells. Solid
phase kinase assay on GST-c-Jun(79) protein substrate. Five hundred mg of protein lysate from control PC12-GDNFR-a (7), or
PC12-GDNFR-a treated, for 10 min, with 100 ng/ml of EGF, NGF or GDNF were precipitated with 1 mg of GST-c-Jun(79) and
incubated with radiolabelled ATP. The results were typical and representative of at least three independent experiments
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and that impairing JNK1 activation by RET is part of
the inhibitory eects of RET mutations associated with
Hirschsprung’s disease.
The pathway leading to JNK1 activation by Ret diverges
from that leading to ERK2 activation and involves Rho/
Rac-related but not Ras small GTP-binding proteins
The recent observation that Rho-related GTPases
(Rac1 and Cdc42) activate JNK (Coso et al., 1995a;
Minden et al., 1995), prompted us to investigate if
these GTPases participate to Ret signalling. As a tool
to inhibit Rho-like GTPases, we used molecular
constructs encoding either RhoGDI (guanine nucleo-
tide dissociation inhibitor) or the catalytic domain of
RhoGAPp190 (RhoGAPdp190) (Coso et al., 1995a,
reviewed by Boguski and McCormik, 1993; Hall, 1994;
Lamarche and Hall, 1994). These plasmids were
transfected in COS-1 cells together with HA-JNK1
and RET/MEN2A plasmids. As shown in Figure 6a,
both of them drastically reduced JNK1 activation by
RET/MEN2A without aecting Ret/MEN2A and
JNK1 expression. Then, we used an expression vector
encoding a dominant negative mutant of Cdc42
(N17Cdc42) (Coso et al., 1995a). This dominant
negative mutant, when transiently transfected in
COS-1 cells, blocked JNK1 activation elicited by
RET/MEN2A (Figure 6b). These results indicated
that Ret signals to JNK1 are delivered through Rho-
related GTPases and, among them, by Cdc42. We also
examined whether Ras plays a key role in JNK1
activation by Ret, using a dominant negative mutant of
Ras (N17Ras). JNK1 response to RET/MEN2A was
not aected by expression N17Ras (Figure 6b). When
we used, in the COS-1 transient expression assay, an
HA-epitope tagged ERK2 Ret/MEN2A resulted to be
a potent activator of ERK2, as evaluated by using the
myelin basic protein (MBP) as a substrate (Figure 6c).
However, at a variance from JNK1, ERK2 induction
by RET/MEN2A was severely impaired by N17Ras
and not by N17Cdc42 expression (Figure 6c). In Figure
6b and c it is also shown that the various constructs
were eciently expressed in the transfected COS-1
cells.
Ret tyrosine residue 1062 is part of a docking site
for the Shc phosphotyrosine binding (PTB) domain.
Mutation of tyrosine 1062 abrogates both Shc binding
to Ret and Shc tyrosine phosphorylation induced by
Ret (Asai et al., 1996; Lorenzo et al., 1997; Arighi et
al., 1997; Melillo et al., in preparation). We
constructed a Y1062F Ret/MEN2A protein mutant
(RET/MEN2AY1062F) and we confirmed that, when
expressed in COS-1 cells, it was correctly synthesized
(Figure 7a, lower). Moreover, an immunoprecipitation
with anti-Ret followed by blotting with anti-phospho-
tyrosine antibodies, indicated that, as reported (Asai et
al., 1996; Lorenzo et al., 1997; Arighi et al., 1997),
Y1062F mutation did not alter the intrinsic kinase
activity of Ret/MEN2A (see for an example Figure
7b). As expected, Y1062F mutation abrogated in vitro
binding of Ret/MEN2A to the PTB domain of Shc
(Figure 7a, upper). Thus, we co-transfected COS-1 cells
with RET/MEN2A or RET/MEN2AY1062F constructs
together with HA epitope tagged JNK1 or ERK2.
Kinase activity of immunoprecipitated JNK1 or ERK2
were then assayed on GST-c-Jun(79) or myelin basic
protein (MBP) as substrates, respectively. ERK
activation was almost completely abolished by the
Y1062F mutation. In contrast, the activation of JNK1
by Ret/MEN2A was unaected by the Y1062F
mutation (Figure 7b).
A dominant negative mutant for SEK interferes with
RET/MEN2A signalling
We have reported that activation of the pNGFI-A-
CAT plasmid is part of the RET signalling in PC12
cells (Califano et al., 1996). NGFI-A is an immediate-
early response gene, whose expression is rapidly
stimulated upon growth factor treatment of PC12
cells (Janssen-Timmen et al., 1989). Thus, we have
evaluated whether JNK activation is involved in RET
signalling by using pNGFI-A-CAT as a target in
transient transfection experiments in PC12 cells. To
interfere with JNK activation, we have used a
dominant negative construct for SEK (pEBG SEK
KR). SEK, also referred to as MKK4 or JNKK1, is
the kinase responsible for JNK activation, by acting
downstream MLK3 and MEKK (Sanchez et al., 1994;
Teramoto et al., 1996). In preliminary experiments we
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Figure 4 Immunocomplex JNK1 kinase assay in NIH3T3 and
PC Cl 3 cells. Two mg of cell lysates from untransfected NIH3T3
stimulated (+) or not (7) with heat shock, and NIH3T3-RET/
MEN2A, or from untransfected PC Cl 3 stimulated (+) or not
(7) with heat shock and PC Cl 3-RET/PTC1 were immunopre-
cipitated with a JNK1-specific polyclonal antibody. Kinase
reaction was performed on the immunoprecipitates using 1 mg
of purified GST-c-Jun(79) as a substrate. An example of one
representative assay (upper) and bar-graphs reporting the average
results of three independent assays (lower) are reported
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have observed that pEBG SEK KR was able to cause a
reduction in JNK1 activation by RET/MEN2A
(Visconti R, unpublished). The average results of
three independent transfections, each performed in
duplicate, are reported in the bar graphs of the Figure
8b and a representative CAT assay is shown in Figure
8a. Transfection of RET/MEN2A resulted in a marked
induction of CAT activity, as reported (Califano et al.,
1996; Carlomagno et al., 1996). Co-expression of
increasing amounts of pEBG SEK KR resulted in a
reduction of pNGFI-A activation by RET/MEN2A.
Discussion
Here we show that Ret tyrosine kinase is able to signal
through the JNK pathway in dierent cell lines.
Several kinases belonging to the JNK family have
been identified (Gupta et al., 1996). Immunoprecipita-
tion with anti-JNK1 antibodies and transient expres-
sion of an epitope-tagged JNK1 construct
demonstrated that JNK1 is at least one of the JNK-
family members activated by Ret. That this ability may
be relevant for the role played by Ret in human
diseases is suggested by several lines of evidence. First,
not only wild type Ret, when triggered by GDNF, but
also chronically activated Ret variants associated with
human tumoral diseases (RET/PTC1, RET/MEN2A,
RET/MEN2B) activate JNK. Particularly, RET/
MEN2B showed a slightly but reproducibly increased
ability of activating JNKs with respect to RET/
MEN2A. On the other side an Hirschsprung’s
mutation, which is known to impair Ret function,
inhibited this action. JNK activation is exerted by
activated RET constructs not only in heterologous cell
systems such as NIH3T3 and COS-1 cells, but also in
other cell types representing specific targets of Ret
action in vivo, such as epithelial thyroid PC Cl 3 and
PC12 cells. Moreover, at least in transiently transfected
Figure 5 RET activation of JNK1 in transiently transfected
COS-1 cells. Subconfluent COS-1 cells were transfected by
electroporation with 1 mg of pcDNA3-HA-JNK1 and 2 mg of
the indicated RET plasmids. Thirty-six hours after transfection,
cells were harvested, 2 mg of cell lysates were immunoprecipitated
with anti-HA antibody (12CA5), and an immunocomplex JNK1
assay was performed on GST-c-Jun(79) substrate. COS-1
transfected with HA-JNK1 alone (7), with HA-JNK1 and the
empty vector (LTR), or with HA-JNK1 and then subjected to
heat shock (428C, 30 min) (+) were used as negative and positive
controls, respectively. Average results of at least four independent
transfections are reported. Parallel samples (500 mg) immunopre-
cipitated with anti-HA and blotted with anti-JNK1 demonstrated
equal expression of the HA-JNK1 protein (not shown). Also Ret
expression was demonstrated by immunoblot (not shown)
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Figure 6 RET activation of JNK1 or of ERK2 in COS-1 cells is
mediated by Rho-related or by Ras small GTPases, respectively.
(a, b) Subconfluent COS-1 cells were transfected by electropora-
tion with 1 mg pcDNA3-HA-JNK1, 2 mg of RET/MEN2A and,
when indicated, with 2 mg of RhoGAPdp190, RhoGDI,
N17Cdc42, or N17Ras plasmids. Thirty-six hours after transfec-
tion, cells were harvested and an immunocomplex JNK1 assay
was performed on GST-c-Jun(79) substrate. Vector transfected
(LTR) COS-1 were used as a negative control. Protein extracts
(500 mg) immunoprecipitated with anti-HA and blotted with anti-
JNK1, immunoprecipitated and blotted with anti-Ret, or blotted
with anti-Ras or anti-Cdc42 antibodies demonstrated equal
expression of the constructs among the dierent samples. (c)
subconfluent COS-1 cells were transfected by electroporation with
1 mg pcDNA3-HA-MAPK, 2 mg of RET/MEN2A and, when
indicated, with 2 mg of N17Cdc42 or N17Ras plasmids. Thirty-six
hours after transfection, cells were harvested and an immuno-
complex ERK2 assay was performed on myelin basic protein
(MBP) as a substrate. A Western blot detected with anti-Ras or
anti-Cdc42 antibodies demonstrated equal expression of the
constructs among the dierent samples. The results were typical
and representative of two independent experiments
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PC12 cells, JNK activation seemed to be important for
Ret signalling, since a dominant negative mutant for
SEK impaired Ret ability of inducing an immediate-
early gene promoter (pNGFI-A) stimulation. However,
at a variance from NIH3T3 and PC Cl 3 cells, adoptive
expression of chronically active RET mutants (RET/
MEN2A and RET/MEN2B, Califano et al., 1996) was
unable to induce JNK activity in PC12 cells (data not
shown). We do not known why chronic stimulation of
Ret is uneective in activating JNK in PC12 cells.
Expression of the JNK1 protein was unaected by
RET/MEN2A and RET/MEN2B, but it is possible
that other components of the JNK activating
machinery are down regulated upon the neuronal
dierentiation induced by chronic RET activation.
As in the case of other receptor tyrosine kinases
(EGFR, as an example), Ret activation of JNK is
mediated by GTPases of the Rho/Rac family (Coso et
al., 1995a). In fact, negative regulators of these
molecules (RhoGAP and RhoGDI) and a dominant
negative construct for Cdc42 impaired JNK activation
by Ret. Experiments conducted with other dominant
negative constructs demonstrated that Rac1 is also
involved in Ret activation of JNK1 and excluded that
Rho could be another of such involved small GTPases
(data not shown).
Several pieces of evidence indicate that ERKs and
JNKs activities are dierently regulated. Ha-ras, which
is sucient for full ERK activation, leads only to
partial JNK activation and, on the other side, Rho/
Rac-family proteins do not have a considerable eect
on ERK2 activity (Coso et al., 1995a). Here, we report
data indicating that these two pathways, in the case of
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Figure 7 (a) In vitro binding of Ret/MEN2A proteins to the PTB
domain of Shc. Subconfluent COS-1 cells were transfected with
5 mg of the indicated RET constructs and lysed 48 h after
transfection. Two mg of protein lysate were incubated with 5 mg
of Sepharose-bound GST-PTB (Shc) recombinant protein and
subjected to SDS–PAGE. The resulting immunoblot was
detected with anti-Ret antibodies (upper). One hundred mg of
protein lysate was used for a Western blot to confirm the equal
expression of the dierent Ret proteins (lower). (b) Activation of
JNK1 or ERK2 by wild type or Y1062F RET/MEN2A
constructs. Subconfluent COS-1 cells were transfected with 1 mg
pcDNA3-HA-JNK1 or 1 mg of an epitope-tagged ERK2
(pcDNA3-HA-MAPK) constructs and 2 mg of the indicated
RET constructs or the empty LTR vector (7). Thirty-six hours
after transfection, cells were harvested, JNK1 activity was
measured as above. ERK2 was immunoprecipitated from 2 mg
of cell lysate with anti-HA antibody (12CA5) and incubated with
labelled ATP and 20 mg of myelin basic protein (MBP). Parallel
samples immunoprecipitated with anti-Ret and blotted with anti-
phosphotyrosine monoclonal antibodies (4G10) were used as a
control. These results are typical and representative of three
independent experiments. Immunoblotting confirmed equal
expression of JNK1 or ERK2 (not shown)
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Figure 8 Inhibition of the RET-induced NGFI-A promoter
activation by a dominant negative SEK mutant. PC12 cells were
transfected with 0.5 mg of pNGFI-A-CAT, 1 mg of RET/MEN2A
and increasing amounts of pEBG SEK KR [SEK (7)], as
indicated. Sixty hours after transfection, total proteins were
isolated and promoter induction determined by CAT assay. (a)
One representative CAT assay is shown. (b) Bar-graphs of the
relative induction are reported as fold increases above the basal
activity of pNGFI-A-CAT reporter gene transfected alone. The
results represent the average of three separate experiments
performed in duplicate. Variation between experiments was less
than 15% of the mean
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RET signalling, are distinct. Ret is able to activate
endogenous Ras and this pathway is relevant for its
mitogenic (Grieco et al., 1995), as well as neuronal
dierentiating activities (Califano et al., 1995). RET
encodes two alternatively spliced protein isoforms 1072
and 1114 amino acids long (Ret1072 and Ret1114) both of
which are able to activate Ras (Santoro et al., 1994;
Grieco et al., 1995; van Weering et al., 1995; our
unpublished observations). Only Ret1114 is able to bind
Grb2 directly, probably through tyrosine residue 1096
(Borrello et al., 1994; Lorenzo et al., 1997; our
unpublished observations). Conversely, both isoforms
are able to bind and to induce the tyrosine
phosphorylation of Shc (Borrello et al., 1994; Lorenzo
et al., 1997). In particular, Ret tyrosine residue 1062,
which is common to both Ret1072 and Ret1114, is part of
a docking site for the Shc phosphotyrosine binding
(PTB) domain (Asai et al., 1996; Lorenzo et al., 1997;
Arighi et al., 1997). Our preliminary results indicate
that Y1062F mutation impairs Ret activation of
endogenous Ras (Visconti et al., unpublished). Here,
we have demonstrated that both a dominant negative
construct for Ras or the substitution of Y1062 with
phenylalanine (Y1062F) abrogates Ret1072-mediated
activation of ERK2, a bona fide downstream eector
of Ras. Conversely, mutation of Y1062 did not alter
Ret signalling to JNK. Together with the observation
that a dominant negative construct for Ras (RasN17)
did not significantly aect JNK activation by Ret,
these data indicate that JNKs activation by Ret is
largely independent on Ras. Thus, although a partial
overlap in pathways leading to JNK and ERK
activation was demonstrated in the case of EGFR
(Coso et al., 1995a), in the case of Ret the two
pathways seem to be completely divergent.
Indirectly, our data also indicate that Ret signalling
involves small GTP-binding proteins other than Ras,
i.e. Cdc42 and Rac1. Rac1 and Cdc42 proteins control
formation of membrane rues (lamellipodia) and
filopodia, respectively (reviewed by Bokoch and Der,
1993). There is also evidence that Rho/Rac-like
proteins eects are not limited to cytoskeleton
organization but are involved in the control of cell
proliferation (Hill et al., 1995). For instance, products
of the vav and dbl oncogenes are bona fide guanine
nucleotide exchange factor for Rac1 (Crespo et al.,
1997), and Cdc42 (Hart et al., 1991), and both
oncogenes are ecient JNK inducers (Minden et al.,
1995; Coso et al., 1995a; Crespo et al., 1997). Finally,
activated Rac1 cooperates with Ras in oncogenic
transformation (Qiu et al., 1995). Molecules involved
in Ret signalling to Rho/Rac family members remain
to be elucidated. One candidate could be the Src kinase
which is activated by Ret (Melillo et al., in
preparation). Indeed, ultraviolet irradiation, a known
inducer of JNK, stimulates c-Src kinase, v-Src is an
ecient JNK activator, and a partial inhibition of v-
Src-mediated transformation is achieved by inactive
forms of JNK1 (Minden et al., 1995; Liu et al., 1996).
Another molecule that could be involved in this
pathway is p190RhoGAP. In fact, it binds and is
phosphorylated upon Ret triggering (Santoro et al.,
1994), and it is a well known modulator of Rho/Rac
activity (Boguski and McCormick, 1993). Finally, PI3
kinase has been described to mediate Ret eects on
cytoskeleton (van Weering and Bos, 1997) and it acts
upstream Rho-related GTPases in the case of PDGFR
signalling (Hawkins et al., 1995). Moreover, both in the
case of epidermal growth factor receptor (Logan et al.,
1997) and of Met (Rodrigues et al., 1997), PI3 kinase
has been demonstrated to be important for JNK
activation. Whether this is also true for Ret remains
to be established.
In conclusion, our findings suggest that signalling
through these small GTPases is likely able to mediate
the potent biological eects exerted by the end product
of naturally occurring oncogenic RET genes in a
variety of cell types.
Materials and methods
Expression plasmids and antibodies
All the RET constructs used in this study are cloned in the
LTR vector and encode the Ret1072 protein isoform. LTR-
RET, encoding wild type Ret, and LTR-RET/MEN2A and
LTR-RET/MEN2B, encoding Ret mutants carrying C634Y
and M918T mutations, respectively, are described else-
where (Santoro et al., 1995). The LTR-RET/MEN2A/
HSCR972 encodes a RET/MEN2A mutant carrying a
Hirschsprung-associated mutation at codon 972 (R972G),
and it has been previously described (Carlomagno et al.,
1996). LTR-RET/MEN2AY1062F encodes a RET/MEN2A
allele in which tyrosine 1062 has been replaced by
phenylalanine. Briefly, to mutagenize Ret tyrosine 1062,
PCR fragments containing the required mutation were
generated by recombinant PCR (Higuchi, 1990) using
LTR-RET as a template. Two primary reactions (a ‘left’
and a ‘right’ reaction) were performed, using standard
PCR conditions (AmpliTaq, Perkin Elmer-Cetus Co). This
yielded two products overlapping in the sequence
corresponding to the reverse primer of the ‘left’ PCR and
the forward primer of the ‘right’ PCR, and the mutation
(TAT?TTT) was introduced as part of these overlapping
PCR primers. Ten ng of the purified PCR products of the
‘left’ and the ‘right’ primary PCR reactions were annealed
and elongated with five PCR cycles (958C 1 min, 378C
2 min, 728C 1 min) followed by 15 cycles of a secondary
PCR, using the 5'- and 3'-most oligonucleotides, as
primers. The recombinant PCR products were cloned in
the pT7Blue T vector (Novagen) and completely sequenced
using the Sequenase Kit (USB). Finally, the fragment
containing the mutation was excised by digestion with XhoI
and MluI and cloned in the LTR-RET/MEN2A plasmid;
this was sequenced in both strands of the region that
underwent genetic manipulations. The primers used were
the following (the mutated nucleotide is in brackets):
Left PCR: 5'- GAGGAGACACCGCTGGTGGTGG -3'
(forward) and 5'-AATTCTGCCA(A)AGAGTTTGTT-3'
(reverse); Right PCR: 5'-AACAAACTCT(T)TGGCAGA-
ATT-3' (forward) and 5'-AAACGCGTACAGCGGTGC-
TAGAATCTAGT-3' (reverse). The expression vector for
rat GDNFR-a (pSJA45-GDNFR-a) is reported elsewhere
(Jing et al., 1996). Expression plasmids for the HA
nonapeptide epitope-tagged JNK1 (pcDNA3-HA-JNK1)
or ERK2 (pcDNA3-HA-MAPK), for the Cdc42
(pcDNA3-N17Cdc42, in which an asparagine residue, in
position corresponding to codon 17 of Ras, was replaced
by a threonine) and the Ras (N17Ras) dominant negative
mutants, and for the two negative regulators of Rho-like
small GTPases (pcDNA3-RhoGAPdp190 and pcDNA3-
RhoGDI) have been already described (Coso et al., 1995a).
The GST-PTB (Shc) construct was a generous gift of PG
Pelicci.
Polyclonal antibodies against Ret were directed to the Ret
tyrosine-kinase domain (Santoro et al., 1994). Anti-Ret
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antibodies were used at 1 mg/ml for immunoprecipitation and
at 0.1 mg/ml for Western blotting. Mouse monoclonal
antibodies anti-HA epitope (clone 12CA5) (Wilson et al.,
1984) were purchased from Boehringer Mannheim, Man-
nheim, Germany. Rabbit polyclonal anti-JNK antiserum was
purchased from Santa Cruz Biotechnology, CA. The 4G10
anti-pTyr monoclonal antibody was purchased from Upstate
Biotechnology, Lake Placid, NY. Anti-Ras and anti-Cdc42
antibodies were provided by Santa Cruz Biotechnology, CA.
Cell culture and transfection experiments
NIH3T3 cells were grown in DMEM supplemented with
10% foetal calf serum (FCS) (GIBCO-BRL). PC12 cells
were grown in RPMI 1640 medium supplemented with
10% horse serum and 5% foetal calf serum (GIBCO-BRL).
The PC Cl 3, thyroid epithelial cell line, was cultured in
modified F12 medium, supplemented with 5% calf serum
(GIBCO-BRL) and six growth factors (thyrotropin,
hydrocortisone, insulin, transferrin, somatostatin and
glycil-histidyl-lysine) (SIGMA Chemical Corporation)
(Fusco et al., 1987). Stable transfectants of the thryoid
(Santoro et al., 1993) and NIH3T3 cells (Santoro et al.,
1995; Carlomagno et al., 1996) with the RET mutants have
been described. To obtain NIH3T3 cells expressing both
RET and GDNFR-a, NIH3T3-RET were transfected with
pSJA45-GDNFR-a and a marker(G418)-selected mass
population was obtained. This transfection was performed
by using the lipofectamine reagent (GIBCO-BRL) follow-
ing manufacturer’s instructions. Briefly, 46105 cells were
plated in 60 mm dishes and incubated with 4 mg of plasmid
and 12 ml of lipofectamine reagent in 1.2 ml OPTIMEM
(GIBCO-BRL). After 4 h, 1.5 ml of DMEM supplemented
with 20% fetal calf serum were added and after 24 h the
incubation mixture was replaced with complete medium
containing G418 for the marker selection. The resulting
cells were demonstrated to express both Ret and GDNFR-
a and to respond to GDNF-triggering with a readily
detectable Ret tyrosine phosphorylation (not shown).
When required, the cells were serum-deprived for 12 h
and then stimulated with 100 ng/ml of human GDNF,
purchased from Alomone Labs., Israel. PC12 cells express
endogenous Ret. To obtain PC12-GDNFR-a, PC12 were
transfected, as previously reported (Califano et al., 1996),
with the pSJA45-GDNFR-a plasmid and a mass popula-
tion was obtained by G418 selection. Ret tyrosine
phosphorylation and neurite outgrowth, upon GDNF
triggering, were demonstrated in the obtained cell
population (not shown). For the JNK assay, PC12-
GDNFR-a were stimulated, for 10 min, with 100 ng/ml
GDNF, EGF or NGF, purchased from Upstate Biotech-
nology. COS-1 cells were maintained in DMEM supple-
mented with 10% FCS. Subconfluent COS-1 cells were
transfected by electroporation (Bio-Rad Gene Pulser,
220 V; 250 mF) with 1 mg pcDNA3-HA-JNK1 or
pcDNA3-HA-MAPK, 2 mg of the dierent RET mutants,
and in some experiments 2 mg of RhoGAPdp190, RhoGDI,
N17Cdc42, and N17Ras plasmids. Cells were incubated for
24 h in complete medium and for 12 h in serum-free
medium.
Jun kinase assay
Cloning and purification of GST-c-Jun(79) substrate has
been previously described (Coso et al., 1995b). This
substrate contains the 79 amino-terminal amino acids of
c-Jun, including the two serines, in position 63 and 73,
that are specifically phosphorylated by the JNKs. For
solid phase kinase assay, subconfluent plates of the
dierent cell lines were incubated over-night in serum-
free medium. When required the cells were subjected to
heat shock (428C, 30 min) before harvesting (Kyriakis et
al., 1994). Cells were washed with ice-cold PBS and lysed
at 48C in a buer containing 25 mM HEPES (pH 7.5),
0.3 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT,
1% Triton-X100, 0.5% sodium deoxycholate, 0.1% SDS,
20 mM b-glycerophosphate, 1 mM sodium vanadate, 1 mM
phenylmethylsulfonyl fluoride, 20 mg/ml aprotinin and
20 mg/ml leupeptin. Cleared lysates (500 mg) were rocked
for 3 h at 48C in the presence of 1 mg of GST-cJun(79)
bound to glutathione-agarose beads. Beads were washed
three times with PBS containing 1% Nonidet P-40 and
2 mM sodium vanadate, once with 100 mM Tris (pH 7.5),
0.5 M LiCl, and once in kinase reaction buer (25 mM
HEPES, pH 7.6, 20 mM MgCl2, 20 mM b-glyceropho-
sphate, 0.1 mM sodium vanadate and 2 mM DTT).
Samples were resuspended in 30 ml of kinase reaction
buer containing 1 mCi of [g-32P]ATP and 20 mM of
unlabelled ATP. After 20 min at 308C the reaction was
terminated by adding 10 ml of 56Laemmli Buer.
Samples were heated at 958C for 5 min and analysed by
SDS-gel electrophoresis on 12% acrylamide gels. Auto-
radiography was performed with the aid of an intensifying
screen. The intensity of signals was analysed at the
phosphorimager (Molecular Dynamics).
Immunocomplex JNK1 activity was determined upon
immunoprecipitating cell lysates (2 mg) (from stable
NIH3T3 or PC Cl 3 transfectants) with a JNK1-specific
polyclonal antibody (Santa Cruz Biotechnology, CA), or cell
lysates from pcDNA3-HA-JNK1 transfected COS-1 with
anti-HA antibody 12CA5 (Boehringer Manneheim, Ger-
many). Cleared lysates were incubated with 2 ml of antibody
for 1 h at 48C. Immunocomplexes were recovered with
protein A-Sepharose (Pharmacia Biotech, Uppsala), and
precipitates were washed six times in lysis buer and then
processed as above. Kinase reaction was performed using
1 mg of purified GST-cJun(79) substrate. Parallel samples
immunoprecipitated with anti-HA and blotted with anti-
JNK1 or immunoprecipitated and blotted with anti-Ret were
used as a control.
ERK kinase assay
ERK activity was assayed in COS-1 cells, transiently
transfected with epitope-tagged ERK2 (pcDNA3-HA-
MAPK), by using 20 mg of myelin basic protein (MBP)
as a substrate, as previously described (Coso et al., 1995b).
Parallel samples immunoprecipitated with anti-Ret and
blotted with anti-phosphotyrosine monoclonal antibodies
(4G10, Upstate Biotechnology) were used as a control of
Ret expression and phosphorylation.
Western blots and in vitro binding experiments
Lysates containing comparable amounts of total cellular
proteins, estimated by a modified Bradford assay (Bio-
Rad), were immunoprecipitated with the required antibody
and analysed by SDS-polyacrylamide gel electrophoresis,
transfer to nitrocellulose, and staining with the required
primary antibody. Immunocomplexes were revealed by
enhanced chemiluminescence detection kit (ECL, Amer-
sham) using anti-rabbit or anti-mouse antiserum coupled
to horseradish peroxidase. Bacterial cultures expressing
recombinant pGEX (Pharmacia) containing the PTB
domain of Shc were grown in LB and induced with
1 mM isopropyl b-D-thiogalactopyranoside for 3 h. The
induced bacteria were lysed by sonication in PBS contain-
ing 10 mg/ml of aprotinin. The recombinant protein was
purified using glutathione-sepharose (Pharmacia). Cells
were lysed and the clarified lysates were incubated with
5 mg of immobilized GST-PTB protein for 60 min at 48C.
Protein complexes were resolved by SDS – PAGE, trans-
ferred to PVDF membranes and detected with anti-Ret
antibodies.
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pNGFI-A-CAT transient assay in PC12 cells
The pNGFI-A-CAT plasmid contains sequences from
position 71150 to +200 of the NGFI-A promoter, fused
to the chloramphenicol acetyl transferase (CAT) gene
(Janssen-Timmen et al., 1989). For transient transfection
assays, 36105 PC12 cells were plated in 60 mm-diameter
tissue culture dishes. Transfection was performed using the
lipofectin reagent following the manufacturer’s instructions
(GIBCO-BRL). The pNGFI-A-CAT plasmid (Janssen-
Timmen et al., 1989) is characterized by a very low basal
level of activity in PC12 cells (lower than 0.5% of
chloramphenicol conversion) (Califano et al., 1996).
Transfections were carried out with 0.5 mg of reporter
plasmid together with 1 mg of RET/MEN2A and increasing
amounts (0, 6, 9 mg) of a dominant negative construct for
SEK (pEBG SEK KR) (Sanchez et al., 1994). The same
DNA concentration was reached by adding various
amounts of the LTR control vector. Cell extracts were
prepared 60 h after transfection and CAT activity was
analysed by thin-layer chromatography with 95% chloro-
form-5% methanol, as previously described (Califano et
al., 1996). Each experimental point was cut from the TLC
plate and counted. For each experiment, the percentage of
conversion to the acetylated form of chloramphenicol [14C]
was then calculated. The results were plotted as promoter
induction relative to the induction exerted by the LTR
vector alone.
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